OR WAIT null SECS
Pharm Exec introduces new monthly columns.
When we redesigned Pharmaceutical Executive in May 2020, we included four new monthly columns: leadership, technology, finance, and strategy. These were topics we felt were top-of-mind for our readers and we wanted to dig deeper into the issues and trends affecting these areas. Over the past two years, we’ve added marketing and managed markets columns.
As we continue to evolve and serve the biopharma community, we’ve decided to make some additional changes to our coverage. We’re folding our existing columns into quarterly rotations with two new, exciting themes. These new columns will focus on the important, timely topics of diversity, equity, and inclusion (DE&I), and environmental, social, and governance (ESG).
Beginning with this issue, we will rotate DE&I, ESG, and leadership columns in one group. Another quarterly group will consist of managed markets, technology, and marketing. We felt that these topics organically fell into these groupings, as many of their themes often overlap.
Our new coverage kicks off this month with our new DE&I column, authored by Denice Torres. Torres is a senior healthcare executive and board member of Resilience, Surface Oncology, 2seventy bio, Glaukos, and Karuna Therapeutics. She is the founder of The Mentoring Place, a free career mentoring program for women, and CEO of The Ignited Company, a change management and DE&I firm. She also has a podcast, “Flip the Tortilla: Lessons for the Underdog at Heart,” on all major platforms. This month, Torres talks about how hybrid workplace decisions can impact DE&I dynamics.
Next month, we will debut our ESG column, contributed by Geralyn Ritter. Ritter is head of external affairs and ESG at Organon. In this role, she focuses on guiding and shaping how the company interacts with key stakeholders and the environment. We’re excited to have her industry input on this important topic.
Separately, our Global Report has been renamed Europe Report, and we’ve added a quarterly Asia-Pacific (APAC) column—debuting this issue—to provide a deeper look into each of these key regions. Our APAC columnist, Bruce Liu, is a partner at Simon-Kucher & Partners and leads the company’s life sciences division in greater China. He has more than 20 years of experience in the APAC healthcare industry across diverse therapeutic areas. In this month’s installment, he discusses China’s growing cell and gene therapies market.
Finally, Barbara Ryan’s insightful finance articles will remain a monthly theme. We value her expert analysis on topics such as the long-term effects of the biotech bear market, mentioned this issue. Longtime contributor Jill Wechsler’s Washington Report, covering important and timely policy news, will also remain monthly.
To recap our revamped coverage, you can expect two rotations: DE&I/ESG/leadership and managed markets/technology/marketing. Asia-Pacific will run quarterly. Europe, finance, and Washington Report will remain monthly features.
As our dynamic industry changes, we will continue to evaluate our coverage to include areas of emerging interest, delivering all the pertinent information you need to be successful.
Elaine Quilici is Pharm Exec’s Editor-in-Chief. She can be reached at firstname.lastname@example.org